| For: | Durairajan SSK, Singh AK, Iyaswamy A. Peroxisome proliferator-activated receptor agonists: A new hope towards the management of alcoholic liver disease. World J Gastroenterol 2024; 30(35): 3965-3971 [PMID: 39351059 DOI: 10.3748/wjg.v30.i35.3965] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v30/i35/3965.htm |
| Number | Citing Articles |
| 1 |
Xi Qiao, Qian Li, Ruiqi Fan, Yujie Cheng, Qingxuan Zeng, Huan Xue, Xiaoli Zhang, Yi Zhang, Yunfeng Liu. Sappanone A, a potential natural inhibitor of PI3K, alleviates metabolic dysfunction-associated steatohepatitis in experimental models. Biochemical Pharmacology 2025; 242 doi: 10.1016/j.bcp.2025.117305
|
| 2 |
Mario Romeo, Claudio Basile, Andrea Imperatore, Giambattista Mozzi, Fiammetta Di Nardo, Carmine Napolitano, Paolo Vaia, Luigi Di Puorto, Mattia Indipendente, Marcello Dallio, Alessandro Federico. Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Chronic Liver Diseases: Translating Mechanistic Insights into Clinical Practice and Future Perspectives. Cells 2026; 15(14) doi: 10.3390/cells15141292
|
| 3 |
Gurleen Kaur, Rahul Jain, Palak Grover, Zarqa Yasin, Bipneet Singh. Peroxisome Proliferator-Activated Receptor Agonists in Primary Biliary Cholangitis and Other Liver Diseases: Mechanisms, Clinical Evidence, and Future Directions. Livers 2026; 6(4) doi: 10.3390/livers6040077
|